A blockbuster drug class that includes Ozempic, Wegovy and Trulicity is pioneering avenues in the healthcare industry and redefining obesity care as the weight loss therapy market stretches toward $100 billion.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
